Video

Next-generation imaging and node-positive prostate cancer

Author(s):

Urology Times staff

Jason Zhu, MD, a medical oncologist at Levine Cancer Institute, part of Atrium Health, discusses how next-generation imaging, such as PSMA-PET imaging, is critical to advancing personalized medicine in patients with lymph node–positive prostate cancer after prostatectomy.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Related Content
64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer
March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke
The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants priority review to 89Zr-DFO-girentuximab for kidney cancer imaging
February 26th 2025

FDA grants priority review to 89Zr-DFO-girentuximab for kidney cancer imaging

Hannah Clarke
The PDUFA date is August 27, 2025.
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
February 21st 2025

Piflufolastat F18 yields high detection rate even at low PSA levels for prostate cancer

Benjamin P. Saylor
Total detection rate was 36% (13/36) in the ultralow PSA group and 51% (47/93) in the low-PSA group.
Real-world data show impact of piflufolastat F18 on prostate cancer management
February 20th 2025

Real-world data show impact of piflufolastat F18 on prostate cancer management

Hannah Clarke
The results encompassed the first 100 patients enrolled in the registry.
FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC
February 19th 2025

FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC

Hannah Clarke
The designation is supported by preliminary data from the ongoing phase 1/2a SECuRE trial.
© 2025 MJH Life Sciences

All rights reserved.